Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith T Flaherty

Showing results (181-190 of 418) with videos related to

Pageof 42
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2015
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805Naomi B Haas, Judith Manola, Bonnie Ky, et al.
European Journal of Cancer (Oxford, England : 1990)|May 19, 2015
Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progressionIgor Puzanov, Ravi K Amaravadi, Grant A McArthur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain MetastasesRavi K Amaravadi, Lynn M Schuchter, David F McDermott, et al.
Biorxiv : the Preprint Server for Biology|May 25, 2026
Genomic, Clinical, and Spatial Predictors of Durable Response to BRAF/MEK Inhibition in <i>BRAF</i> -Mutant MelanomaYingxiao Shi, Alexander Savchenko, Jan Christoph Brase, et al.
European Journal of Cancer (Oxford, England : 1990)|May 4, 2020
Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinomaEileen M O'Reilly, Diletta Barone, Devalingam Mahalingam, et al.
Science Advances|June 24, 2021
Rejection of benign melanocytic nevi by nevus-resident CD4<sup>+</sup> T cellsErik B Schiferle, Se Yun Cheon, Seokjin Ham, et al.
Nature Communications|October 16, 2021
Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanomaKuang Du, Shiyou Wei, Zhi Wei, et al.
Molecular Cancer Therapeutics|September 16, 2008
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomasKeiran S M Smalley, Mercedes Lioni, Maurizia Dalla Palma, et al.
Cancer Cell|July 25, 2025
Reduction of TRAIL-Induced Mcl-1 and cIAP2 by c-Myc or Sorafenib Sensitizes Resistant Human Cancer Cells to TRAIL-Induced DeathM Stacey Ricci, Seok-Hyun Kim, Kazuhiro Ogi, et al.
Cancer|March 1, 2014
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsAllison Ackerman, Oliver Klein, David F McDermott, et al.
Pageof 42

Showing results (181-190 of 418) with videos related to

Sort By:
Pageof 42
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2015
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805Naomi B Haas, Judith Manola, Bonnie Ky, et al.
European Journal of Cancer (Oxford, England : 1990)|May 19, 2015
Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progressionIgor Puzanov, Ravi K Amaravadi, Grant A McArthur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain MetastasesRavi K Amaravadi, Lynn M Schuchter, David F McDermott, et al.
Biorxiv : the Preprint Server for Biology|May 25, 2026
Genomic, Clinical, and Spatial Predictors of Durable Response to BRAF/MEK Inhibition in <i>BRAF</i> -Mutant MelanomaYingxiao Shi, Alexander Savchenko, Jan Christoph Brase, et al.
European Journal of Cancer (Oxford, England : 1990)|May 4, 2020
Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinomaEileen M O'Reilly, Diletta Barone, Devalingam Mahalingam, et al.
Science Advances|June 24, 2021
Rejection of benign melanocytic nevi by nevus-resident CD4<sup>+</sup> T cellsErik B Schiferle, Se Yun Cheon, Seokjin Ham, et al.
Nature Communications|October 16, 2021
Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanomaKuang Du, Shiyou Wei, Zhi Wei, et al.
Molecular Cancer Therapeutics|September 16, 2008
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomasKeiran S M Smalley, Mercedes Lioni, Maurizia Dalla Palma, et al.
Cancer Cell|July 25, 2025
Reduction of TRAIL-Induced Mcl-1 and cIAP2 by c-Myc or Sorafenib Sensitizes Resistant Human Cancer Cells to TRAIL-Induced DeathM Stacey Ricci, Seok-Hyun Kim, Kazuhiro Ogi, et al.
Cancer|March 1, 2014
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsAllison Ackerman, Oliver Klein, David F McDermott, et al.
Pageof 42